NCT01793818 (EVATAT) is a Phase 1/Phase 2 clinical trial of Tat Oyi in AIDS, sponsored by BIOSANTECH.

Who is sponsoring NCT01793818?

NCT01793818 is sponsored by BIOSANTECH.

What drugs are being tested in NCT01793818?

Interventions in NCT01793818: Tat Oyi.

Is NCT01793818 still recruiting?

NCT01793818 is currently status unknown. Last updated 9 February 2016.

Last reviewed 2016-02-09 · How we verify

NCT01793818: EVATAT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein

Status unknown Phase 1/Phase 2 Last updated 9 February 2016

What this trial tests

Phase 1/Phase 2 trial testing Tat Oyi in AIDS in 50 participants. Status unknown.

Timeline

1 February 2013

Primary endpoint
1 March 2016

1 March 2016

Quick facts

Lead sponsor	BIOSANTECH
Phase	Phase 1/Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	1 February 2013
Primary completion	1 March 2016
Estimated completion	1 March 2016
Sites	1 location across France

Drugs / interventions tested

Tat Oyi — full drug profile →

Conditions studied

AIDS — all drugs for AIDS →

Sponsor

BIOSANTECH — full company profile →

Who can join

Adults 18 to 64, any sex, with AIDS. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Optimal vaccine dose (phase I/II)
Time frame: Two years
No undesirable events due to vaccination and viremia remaining \< 100 copies/ml after interruption of ART.

Sponsor's own description

Tat Oyi vaccination on seropositive patients could help their immune system to recognize and neutralize Tat. The neutralization of extra cellular Tat should help the cellular immune response to eliminate HIV-1 infected cells.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Current progress in the development of prophylactic and therapeutic vaccines.
Li T, Qian C, Gu Y, Zhang J, et al · · 2023 · cited 39× · PMID 36469218 · DOI 10.1007/s11427-022-2230-4
Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.
Loret EP, Darque A, Jouve E, Loret EA, et al · · 2016 · cited 19× · PMID 27036656 · DOI 10.1186/s12977-016-0251-3
Perspectives for immunotherapy: which applications might achieve an HIV functional cure?
Vieillard V, Gharakhanian S, Lucar O, Katlama C, et al · · 2016 · cited 10× · PMID 26950274 · DOI 10.18632/oncotarget.7793

Verify or expand the search:

Other recruiting trials for AIDS

Currently open trials in the same condition.

NCT05373758 — A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa · NA · recruiting
NCT05939167 — Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage · Phase 1, PHASE2 · recruiting
NCT06137196 — Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia · recruiting
NCT06145841 — Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies · recruiting
NCT05988879 — Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01793818 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BIOSANTECH
Last refreshed: 9 February 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01793818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing